Thank you, Andrew.
Let's bladder Association for the research advanced Cancer were highlight the cancer Research. please. for year's slide, information to setting new meeting to go ahead at on metastatic We the next and American new the able this the annual
action. presentation first was involvement the The cells therapeutic of presentation poster killer of detailing a our mechanism natural in
clinical were wherein able The we the was our cancer bladder podium indication. presentation basket the advanced detail to from metastatic see a experience second presentation, with trial
still therapeutic slide, the to and very T-cells. function. clinical a absence that maveropepimut-S related of incited anti-tumor Natural cells able B action. deepen our killer of may research, were cell mechanism was killer this translational to know, that maveropepimut-S of our us in therapeutic understanding allows Ultimately, cells cells natural are that also able show mechanism From tumor Collectively, much different is to natural what and you are Next killer efficacy, please? able action, killer we to tissues. by trigger we way richer T-cells natural cells, in kill than we're in appreciate a models, as were helps So to broaden pre modality. to in show -clinical involved in for knowing and
And so bear able we're multiple killing to now using modalities to maveropepimut-S. of bring
able the were data bladder We trial. Next cancer slide, show please? the from to also
a basket You will is this trial. recall
it in While across striking. we many most setting clinical cancer evidenced the the the cases was saw basket efficacy the of efficacy bladder trial, benefit the in in was
with graduate see stage of two was for or more complete to X XX additional we three to dose then have In attributed injection has Originally designed We ultimately involved there actually was were adverse our XX grade to well severe first that low events second the trial. and the two typical responses, experience, [Indiscernible] [Indiscernible]. when this X We reactions. on for responders common no a treatment trial. partial this very been saw [Indiscernible] seen and tolerated the responses. trial, most side five and routinely with reactions of patients, combine intermittent and responses patients we trial As the clinical adverse
were site metastasis well. in were only liver Importantly, node metastasis this that as lesions responsive but not lymph
today, As ultimately we broke important realize we able to entire down were this study. a of very aspect
in progress of Our think very that one responders KOLs very aspect excited aspect of in trial responders our completely a an And our already actually have I partial are inhibitive important immune and therapy about. checkpoint this through was benefit Survivin-specific our fact, seen multiple we've Maveropepimut our therapy evident as patients most T is from in to shown clinical of experience, action. base clinical From benefit the mechanism related who times derived across cell.
plot, right-hand we're the see slide, least of side the patients In scan. plot. you On one fall reached of at lot showing this a who this
So tumor the patient which size an What the valuable start population, baseline at zero. can see had [Indiscernible]. at is you
the dotted in that we stations. You you correct only in more very -- tumor see disease stable can XX%, reduced addition, criteria. can see that's have line, [Indiscernible] patients. we here And when when three we of this clearly when responders five additional we than size that
The patient therapy. had slide. patient take came experience. next the individual disease. go patient prior to a back the this not extensive for [Indiscernible] metastatic go example, first to In to received slide. few us Please with want I Let's one
target disease. The us therapy for to -- is four back will go The patient one slide. prior Thank not you. Before one patient to came with please. metastatic designated which please slide receive
we that a sort from than beyond showed of shrink and have durable lesions this target XX% lesions with can slide. responsiveness patient XXX. reduction two The patient some scan, timing node more the first Effectively, lymph on two us Okay. patient we of At have our first The survived baseline. liver and lesions. can out the liver showed us Must response. patient have day
ahead slide. Let's the to go next
second very and now. scan response node patient to we days stay XXX able The fact. for first continues well on Ultimately able profound complete days the a that to showed In survive see beyond this in therapy disease. example, response, XXX us was to about patient were base lymph
is Let's beyond response This well immediately days. very XXX One the that patient We continues example go patient third now, please. responder. this a example. first profound was show here a response saw showed patient this our scan, more. complete And out at example, to to last
Let's next please. go slide, to the
us patient is this patient of case pembrolizumab courses received five reduction, the this -- of therapy. patient only dose CPA. important the study showed disease this profound because patient patient, Importantly, particularly example continues and two The of single one only on
been complete has effectively, So of we have by maveropepimut-S response days the on patient XXX bulk trial, the itself. this for driven
very a case interesting for So us.
in four to might are us. forward of and cancer final clinical a And we indications. ahead very The the summary. you been go [Indiscernible] translational section. pushing network forward particular this recall, slide important for quarter It's as different Let's
VITALIZE. refractory We've indication that lead indication, patients the relapsed trial call enrolled Our first our the in DLBCL is the study. we
To new we accelerate further, We are additional activating continue to enrollment enroll more opening countries sites. and patients.
We of be first from talk in year. to expect to QX results this able study the about
Our AVALON. platinum second the resistant is patient metastatic cancer study in Phase is population. II the DeCidEX space advanced ovarian in called This
dose had had previously complete recall We're QX. study, first only the patients and in data showed the for this checkpoint to have last two had inhibitor the a failed you responses You from opportunities. in we who in durable. therapy. have we on our who protocol received bladder midst that partial advanced responses very were might FDA track single enroll right I responses cancer And metastatic January. patients we different approval first the sites sites to QX The activate and in example, showed now. [Indiscernible]. in activating cancer, of In you We're in bladder patient as include of I wherein
to bladder product, first also clinical our have an earlier product, maveropepimut-S, We we're comparing wherein study our second cancer DPX-SurMAGE. stage
enrolled, to - the So -- in bladder that once the with second begin product. this cohort enrolling cohort non this is maveropepimut-S cancer cohort invasive muscle we'll particular is enrolling is study. now enroll
the as product, surviving tumor the new product MJ recall, both as second antigen. targets may tumor as you well antigen, a nine involves The that
inhibitors of bladder these allows with levered. new we hormone deeply collaborators at resistance in aromatase the tissue pre last to up at is cancer that slide. The we're has It we noted will is beauty Providence, us cancer will survival. receptor-positive to into really in antigens involves a This patients, able under and breast at study cancer aromatase that the been HER-X that This this resection. compare maveropepimut-S in prior of pathology is combining and similar. the this we Maveropepimut non-muscle surgical hand, get -clinical because biopsies the setting, differ expect invasive have new simultaneously. tumor tissue to to to response treatment get study, in data we So of context, regulation two the is where what This with be to often is by insight negative and our dig of the doing level is of study. this antigen The it
surviving treatment letrozole, it reason allow same study, to attack so the our at tumor into invasive stands cells mechanism evaluate surgical non-muscle we early prior much only of to bladder might benefit. more to have and dig tissue then cancer will to tissue if a we biopsies that at can deeply us paired profound This study get have the expresses So tumor resection therapeutic like time and the and we that action.
the only fact, aspect killing first Cancer we are [Indiscernible]. different and understanding coming cell we're killer products our think these Symposium sub results very DPX And the function this of killing platform targeting not to this Antonio two T deepen cells from kill the in types, [Indiscernible] at cells. also immune And Breast [Indiscernible] lastly, to December. listing natural powerful functions of We San cells important study of is very of show presentation Very continue ways. we that this because important and but the in of this
Now Brittany. back to I'll hand it
